PortalPublikationenReal-World Experience of Patient-Relevant Benefits and Treat...

Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study

Standard

Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study. / Klein, Toni Maria; Blome, Christine; Kleyn, C Elise; Conrad, Curdin; Sator, Paul G; Ståhle, Mona; Eyerich, Kilian; Radtke, Marc Alexander; Bundy, Christine; Cordey, Myriam; Griffiths, Christopher E M; Augustin, Matthias.

in: DERMATOLOGY THER, Jahrgang 12, Nr. 1, 01.2022, S. 81-95.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Klein, TM, Blome, C, Kleyn, CE, Conrad, C, Sator, PG, Ståhle, M, Eyerich, K, Radtke, MA, Bundy, C, Cordey, M, Griffiths, CEM & Augustin, M 2022, 'Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study', DERMATOLOGY THER, Jg. 12, Nr. 1, S. 81-95. https://doi.org/10.1007/s13555-021-00628-3

APA

Klein, T. M., Blome, C., Kleyn, C. E., Conrad, C., Sator, P. G., Ståhle, M., Eyerich, K., Radtke, M. A., Bundy, C., Cordey, M., Griffiths, C. E. M., & Augustin, M. (2022). Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study. DERMATOLOGY THER, 12(1), 81-95. https://doi.org/10.1007/s13555-021-00628-3

Vancouver

Klein TM, Blome C, Kleyn CE, Conrad C, Sator PG, Ståhle M et al. Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study. DERMATOLOGY THER. 2022 Jan;12(1):81-95. https://doi.org/10.1007/s13555-021-00628-3

Bibtex

@article{e5ae4faddc3a498f89c7c0197c68fbd0,
title = "Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study",
abstract = "INTRODUCTION: In the real-world APPRECIATE study (NCT02740218), most patients with psoriasis demonstrated notable improvements on disease severity measures and reported clinically meaningful treatment benefits with apremilast.OBJECTIVE: We aim to further describe patient-relevant needs and benefits and patient satisfaction with apremilast, including subgroup analyses based on patient characteristics.METHODS: APPRECIATE, a multinational, retrospective, cross-sectional study, enrolled patients with chronic plaque psoriasis who started apremilast according to the European label. Patient Benefit Index (PBI; range 0 (no patient-relevant benefit) to 4 (maximum patient-relevant benefit), global PBI score ≥ 1 indicating minimum patient-relevant benefit and ≥ 3 indicating high benefit) and nine-item Treatment Satisfaction Questionnaire for Medication (TSQM-9; range 0-100) were assessed 6 (± 1) months after apremilast initiation and summarized descriptively. Relationships between global PBI and TSQM-9 assessments were analyzed by Pearson correlations.RESULTS: Of 480 enrolled patients, 347 (72.3%) had remained on apremilast at 6 (± 1) months; 90.9% (300/330) achieved global PBI score ≥ 1. Mean (standard deviation) global PBI score was 2.8 (1.2). Higher achievement of global PBI score ≥ 3 was observed in patients with no prior treatments (61.1% (22/36)) or prior phototherapy (64.6% (42/65)) versus prior conventional systemic (54.4% (100/184)) or biologic (38.6% (17/44)) treatment. Strong correlations were observed between the global PBI score and the TSQM-9 global satisfaction and effectiveness subscale scores.CONCLUSION: Patients continuing apremilast for 6 (± 1) months in APPRECIATE reported patient-relevant treatment benefits. Findings suggest that receiving apremilast earlier versus later in treatment management is consistent with greater improvements in patient-relevant treatment outcomes.",
author = "Klein, {Toni Maria} and Christine Blome and Kleyn, {C Elise} and Curdin Conrad and Sator, {Paul G} and Mona St{\aa}hle and Kilian Eyerich and Radtke, {Marc Alexander} and Christine Bundy and Myriam Cordey and Griffiths, {Christopher E M} and Matthias Augustin",
note = "{\textcopyright} 2021. The Author(s).",
year = "2022",
month = jan,
doi = "10.1007/s13555-021-00628-3",
language = "English",
volume = "12",
pages = "81--95",
journal = "DERMATOLOGY THER",
issn = "2193-8210",
publisher = "Springer",
number = "1",

}

RIS

TY - JOUR

T1 - Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study

AU - Klein, Toni Maria

AU - Blome, Christine

AU - Kleyn, C Elise

AU - Conrad, Curdin

AU - Sator, Paul G

AU - Ståhle, Mona

AU - Eyerich, Kilian

AU - Radtke, Marc Alexander

AU - Bundy, Christine

AU - Cordey, Myriam

AU - Griffiths, Christopher E M

AU - Augustin, Matthias

N1 - © 2021. The Author(s).

PY - 2022/1

Y1 - 2022/1

N2 - INTRODUCTION: In the real-world APPRECIATE study (NCT02740218), most patients with psoriasis demonstrated notable improvements on disease severity measures and reported clinically meaningful treatment benefits with apremilast.OBJECTIVE: We aim to further describe patient-relevant needs and benefits and patient satisfaction with apremilast, including subgroup analyses based on patient characteristics.METHODS: APPRECIATE, a multinational, retrospective, cross-sectional study, enrolled patients with chronic plaque psoriasis who started apremilast according to the European label. Patient Benefit Index (PBI; range 0 (no patient-relevant benefit) to 4 (maximum patient-relevant benefit), global PBI score ≥ 1 indicating minimum patient-relevant benefit and ≥ 3 indicating high benefit) and nine-item Treatment Satisfaction Questionnaire for Medication (TSQM-9; range 0-100) were assessed 6 (± 1) months after apremilast initiation and summarized descriptively. Relationships between global PBI and TSQM-9 assessments were analyzed by Pearson correlations.RESULTS: Of 480 enrolled patients, 347 (72.3%) had remained on apremilast at 6 (± 1) months; 90.9% (300/330) achieved global PBI score ≥ 1. Mean (standard deviation) global PBI score was 2.8 (1.2). Higher achievement of global PBI score ≥ 3 was observed in patients with no prior treatments (61.1% (22/36)) or prior phototherapy (64.6% (42/65)) versus prior conventional systemic (54.4% (100/184)) or biologic (38.6% (17/44)) treatment. Strong correlations were observed between the global PBI score and the TSQM-9 global satisfaction and effectiveness subscale scores.CONCLUSION: Patients continuing apremilast for 6 (± 1) months in APPRECIATE reported patient-relevant treatment benefits. Findings suggest that receiving apremilast earlier versus later in treatment management is consistent with greater improvements in patient-relevant treatment outcomes.

AB - INTRODUCTION: In the real-world APPRECIATE study (NCT02740218), most patients with psoriasis demonstrated notable improvements on disease severity measures and reported clinically meaningful treatment benefits with apremilast.OBJECTIVE: We aim to further describe patient-relevant needs and benefits and patient satisfaction with apremilast, including subgroup analyses based on patient characteristics.METHODS: APPRECIATE, a multinational, retrospective, cross-sectional study, enrolled patients with chronic plaque psoriasis who started apremilast according to the European label. Patient Benefit Index (PBI; range 0 (no patient-relevant benefit) to 4 (maximum patient-relevant benefit), global PBI score ≥ 1 indicating minimum patient-relevant benefit and ≥ 3 indicating high benefit) and nine-item Treatment Satisfaction Questionnaire for Medication (TSQM-9; range 0-100) were assessed 6 (± 1) months after apremilast initiation and summarized descriptively. Relationships between global PBI and TSQM-9 assessments were analyzed by Pearson correlations.RESULTS: Of 480 enrolled patients, 347 (72.3%) had remained on apremilast at 6 (± 1) months; 90.9% (300/330) achieved global PBI score ≥ 1. Mean (standard deviation) global PBI score was 2.8 (1.2). Higher achievement of global PBI score ≥ 3 was observed in patients with no prior treatments (61.1% (22/36)) or prior phototherapy (64.6% (42/65)) versus prior conventional systemic (54.4% (100/184)) or biologic (38.6% (17/44)) treatment. Strong correlations were observed between the global PBI score and the TSQM-9 global satisfaction and effectiveness subscale scores.CONCLUSION: Patients continuing apremilast for 6 (± 1) months in APPRECIATE reported patient-relevant treatment benefits. Findings suggest that receiving apremilast earlier versus later in treatment management is consistent with greater improvements in patient-relevant treatment outcomes.

U2 - 10.1007/s13555-021-00628-3

DO - 10.1007/s13555-021-00628-3

M3 - SCORING: Journal article

C2 - 34813044

VL - 12

SP - 81

EP - 95

JO - DERMATOLOGY THER

JF - DERMATOLOGY THER

SN - 2193-8210

IS - 1

ER -